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Abstract
Background—During long-term anticoagulation in atrial fibrillation, temporary interruptions 
(TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been 
well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI, 
and the relationship between anticoagulant and outcomes among patients with TI.
Methods and Results—In the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition 
Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation (ROCKET AF), a randomized, double-blind, double-dummy study of rivaroxaban and 
warfarin in nonvalvular atrial fibrillation, baseline characteristics, management, and outcomes, 
including stroke, non–central nervous system systemic embolism, death, myocardial infarction, 
and bleeding, were reported in participants who experienced TI (3–30 days) for any reason. The 
at-risk period for outcomes associated with TI was from TI start to 30 days after resumption of 
study drug. In 14 236 participants who received at least 1 dose of study drug, 4692 (33%) 
experienced TI. Participants with TI were similar to the overall ROCKET AF population in regard 
to baseline clinical characteristics. Only 6% (n=483) of TI incidences involved bridging therapy. 
Stroke/systemic embolism rates during the at-risk period were similar in rivaroxaban-treated and 
warfarin-treated participants (0.30% versus 0.41% per 30 days; hazard ratio [confidence 
interval]=0.74 [0.36–1.50]; P=0.40). Risk of major bleeding during the at-risk period was also 
similar in rivaroxaban-treated and warfarin-treated participants (0.99% versus 0.79% per 30 days; 
hazard ratio [confidence interval]=1.26 [0.80–2.00]; P=0.32).
Conclusions—TI of oral anticoagulation is common and is associated with substantial stroke 
risks and bleeding risks that were similar among patients treated with rivaroxaban or warfarin. 
Further investigation is needed to determine the optimal management strategy in patients with 
atrial fibrillation requiring TI of anticoagulation.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: 
NCT00403767.
Keywords
anticoagulation; atrial fibrillation; stroke
In patients with atrial fibrillation (AF), anticoagulation reduces the risk of stroke and 
embolic events and improves survival.1–4 Annually, nearly 250 000 AF patients in the 
United States alone require temporary interruption (TI) of anticoagulation for invasive 
procedures,5 acute illness, or bleeding events. Bridging therapy may or may not be pursued 
on the basis of clinical evaluation and physician perception of thrombotic risk versus 
bleeding risk.5,6 Although several clinical studies have examined the characteristics of 
patients with TI of anticoagulant therapy and the potential need for bridging therapy,7–10 
there are limited data regarding downstream thrombotic and bleeding outcomes in these 
populations,11 and even less is known about TI of novel oral anticoagulants in 
periprocedural settings.12
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The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET 
AF) demonstrated that rivaroxaban was noninferior to warfarin in the prevention of stroke 
and systemic thromboembolic events in moderate- to high-risk participants with nonvalvular 
AF.3 During the course of the trial, many participants required TI of anticoagulant 
medication. The objectives of the present analyses are to characterize those participants who 
required TI of oral anticoagulation, to examine reasons for TI, to describe patterns of 
bridging therapy, and to evaluate outcomes associated with rivaroxaban and warfarin.
Methods
Patient Population
The design, methods, and primary results of the ROCKET AF trial have been described 
previously.13 Briefly, ROCKET AF was a randomized, double-blind, double-dummy trial 
comparing fixed-dose rivaroxaban (20 mg daily or 15 mg daily in participants with a cre-
atinine clearance of 30–49 mL/min) versus dose-adjusted warfarin (maintaining an 
international normalized ratio in the therapeutic range [2.0–3.0]) in participants with 
nonvalvular AF and moderate to high risk for stroke. The principal efficacy outcome was the 
occurrence of any stroke or non–central nervous system (CNS) systemic embolism. The 
principal safety outcome was the composite of International Society on Thrombosis and 
Hemostasis major bleeding and nonmajor clinically relevant (NMCR) bleeding.14
The ROCKET AF trial was supported by research grants from Johnson & Johnson 
Pharmaceutical Research and Development (Raritan, NJ) and Bayer Healthcare AG 
(Leverkusen, Germany). The Duke Clinical Research Institute (Durham, NC) coordinated 
the trial and performed the statistical analyses for this article independent of the sponsors. 
All appropriate national regulatory authorities and ethics committees at participating centers 
approved the study. An international executive committee designed the study and takes 
responsibility for the accuracy and completeness of the analyses.
For baseline summaries and occurrence of TI, all participants in the safety on-treatment 
population, defined as those who were randomized and received at least 1 dose of study 
drug, were included. All other analyses included the subset of patients with 1 or more TIs.
Outcomes and Definitions
TI of oral anticoagulation was defined as cessation of study drug for ≥ 3 days, due to any 
cause without transition to an open-label anticoagulant, with resumption of study drug 
within 30 days. The at-risk period for outcomes associated with TI was defined as the 
duration of the TI plus 30 days after the resumption of study drug. This period was chosen in 
efforts to evaluate the outcomes associated with TI and the time period after resumption of 
study drug. This is also the time frame recommended by a task force consensus document 
derived from available data.15 In cases in which study drug was resumed and stopped again 
within 30 days, the first at-risk period extended only to the day before the new interruption. 
Information on the type of procedure, date of procedure, and details concerning study drug 
interruption were captured in electronic case report form for the ROCKET AF trial. Invasive 
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procedures were defined as any percutaneous or surgical procedure that would typically 
require cessation of warfarin. These included coronary angiography, percutaneous coronary 
intervention, peripheral vascular intervention, surgery, endoscopy, electrophysiology 
procedures, endoscopy/colonoscopy, and tissue biopsies as well as major dental procedures.
Stroke was defined as a sudden, focal neurological deficit resulting from a presumed 
cerebrovascular cause that is not reversible within 24 hours and not due to a readily 
identifiable cause, such as a tumor or seizure. Non-CNS systemic embolism was defined as 
abrupt vascular insufficiency associated with clinical or radiological evidence of arterial 
occlusion in the absence of other likely mechanisms (eg, trauma, atherosclerosis, or 
instrumentation). Myocardial infarction was defined by clinical symptoms consistent with 
myocardial infarction and cardiac biomarker elevation (troponin I or T, creatine kinase–
muscle and brain subunit) greater than the upper limit of normal, the development of new 
pathological Q waves in ≥2 contiguous ECG leads, or confirmed by autopsy.
Major bleeding was defined as clinically overt bleeding associated with any of the 
following: fatal outcome, involving a critical site (ie, intracranial, intraspinal, intraocular, 
pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal), or 
clinically overt bleeding associated with a fall in hemoglobin concentration of ≥2 g/dL or 
leading to transfusion of ≥2 U of packed red blood cells or whole blood.14 NMCR bleeding 
was defined as overt bleeding not meeting the criteria for major bleeding but associated with 
medical intervention, unscheduled contact with a physician (visit or telephone call), 
temporary (ie, by delaying the next study drug administration) cessation of study drug, pain, 
or impairment of daily activities.14 All other overt bleeding episodes not meeting the criteria 
for major or NMCR bleeding are classified as minor bleeding. All primary and secondary 
outcome events were adjudicated by a blinded, independent multispecialty clinical end point 
committee as part of the ROCKET AF trial.
In the ROCKET AF trial protocol, investigators were given the option to utilize bridging 
therapy in appropriate participants at intermediate to high risk for thromboembolic events 
(considered as those with >2 risk factors for stroke) that experienced TI. Both use of 
bridging therapy and selection of medications were left to the investigators’ discretion. 
Information on the use of bridging therapy was collected through the ROCKET AF trial 
electronic case report form by matching the dates of medication use forms (specifically for 
heparins and other parental or subcutaneous anticoagulants) to TI dates.
Statistical Analyses
Baseline characteristics are summarized according to TI status, randomized treatment, and 
use of bridging therapy. Continuous variables are shown as median (25th, 75th percentile), 
and categorical variables are shown as frequency (percentage). Among participants with at 
least 1 TI, characteristics of participants who received bridging therapy at least once were 
compared with those of participants who did not with the use of Wilcoxon rank sum tests or 
Pearson 2 tests as appropriate. Because early study drug discontinuations resulted in a high 
level of early censoring, rates of temporary interruption at different times were estimated by 
cumulative incidence functions that treat early permanent drug discontinuation and death as 
competing risks to TI. Cumulative incidence curves were compared with the Gray test.16
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Outcomes occurring during TI risk periods are summarized by randomized treatment and by 
bridging therapy as number of events and event rates per 30 days. Association of 
randomized treatment with risk of outcome was assessed with Cox proportional hazards 
models in which each TI was an observation and that used robust sandwich variance 
estimators to account for correlation of multiple TIs within participants. Each participant 
could meet each end point only once; when a participant met an end point, subsequent TIs 
for that participant were not included in that model. Risk relationships are expressed as 
hazard ratios with 95% confidence intervals. Relationships between bridging therapy and 
risk of outcomes were not formally tested because of the very small number of events within 
the small subgroup of bridged TIs and complexities caused by the occurrence of both 
bridged and unbridged TIs in the same patients.
Sensitivity Analyses
Given concern for possible confounding for TIs associated with an adverse bleeding event, 
resulting in higher reported resultant bleeding risks, sensitivity analyses were performed to 
evaluate risks of bleeding in the subset of TI participants, excluding those TIs caused by an 
adverse bleeding event. Additional sensitivity analyses were also performed to evaluate risk 
relationships in the surgical/invasive procedure TI population alone. All analyses were 
performed with the use of SAS software version 9.2 (SAS Institute Inc, Cary, NC). A 2-
sided P value <0.05 was considered statistically significant.
Results
Temporary Interruption Population
A total of 4692 participants in ROCKET AF (33% of 14 236 who were randomized and 
received study drug) experienced 7555 episodes of TI, of which 3393 occurred in 
participants treated with rivaroxaban and 4162 in participants treated with warfarin. 
Warfarin-treated participants experienced higher rates of TI over a 24-month follow-up 
period compared with rivaroxoban-treated participants (Figure 1; P<0.0001). The median 
duration of TI was 5 (4, 9) days. Among those with TI, 63% had 1 TI, 24% had 2 episodes, 
and 13% had ≥3 episodes of TI.
Baseline patient characteristics are reported in Table 1. In general, participants who 
experienced TI were similar to the overall population of participants, with comparable 
median age, creatinine clearance, time of exposure to treatment, mean CHADS2 scores, and 
rates of hypertension, diabetes mellitus, congestive heart failure, prior stroke, prior 
myocardial infarction, and prior vitamin K antagonist use. Participants with TI receiving 
rivaroxaban were similar to those receiving warfarin for each of these characteristics as well.
TI Characteristics
The reasons for TI in the ROCKET AF trial are shown in Table 2. Forty percent experienced 
TI for a surgical or invasive procedure, 25% of participants had TI for an adverse event 
unrelated to bleeding, and 13% had TI for an adverse bleeding event. The remaining (12%) 
were attributed to subject error (majority), site error, and logistic difficulties. These results 
were similar when only the first episode of TI was considered.
Sherwood et al. Page 5
Circulation. Author manuscript; available in PMC 2014 November 06.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Among TIs for a surgical or invasive procedure, the interruption was prompted by a variety 
of invasive procedures (Figure 2). The most common causes of TI were colonoscopy or 
gastrointestinal endoscopic procedures (17%) and dental work (17%). Various abdominal, 
thoracic, and orthopedic surgeries (13%), electrophysiology procedures (9%), and 
dermatologic procedures (11%) also contributed significantly, whereas angiography, 
percutaneous coronary intervention, peripheral intervention (4%), and eye surgery (8%) 
contributed to a lesser degree. Eleven percent of TIs were due to surgical/invasive 
procedures in which details of the procedure are unknown. There were no meaningful 
differences in the frequency of different types of invasive procedures that prompted TI 
between rivaroxaban- and warfarin-treated patients (Figure I in the online-only Data 
Supplement).
Bridging Patterns and Patient Characteristics
Only 9% (n=431) of patients with TI during the ROCKET AF trial received bridging 
therapy during at least 1 TI. Most patients with TI who received bridging therapy were 
treated with low-molecular-weight heparin (98.6%), whereas the remaining patients were 
treated with fondaparinux (1.4%). The median duration of bridging therapy was 6 (4, 9) days 
(Table 2). Patient characteristics according to the presence or absence of bridging therapy 
are summarized in Table 3. Bridged and unbridged participants had similar rates of 
hypertension, diabetes mellitus, prior stroke, and congestive heart failure. Participants who 
received bridging therapy were older, were less commonly on prior aspirin therapy, more 
commonly had prior exposure to vitamin K antagonists, and had slightly higher mean 
CHADS2 risk scores (3.52 versus 3.40; P=0.009). These results were similar when only the 
first episode of TI was considered.
Outcomes in TI
By Treatment Arm—Outcomes according to randomized treatment assignment are shown 
in Table 4. The risk of stroke or non-CNS systemic embolism during any at-risk period of TI 
was not significantly different in rivaroxaban-treated patients versus warfarin-treated 
patients. Risks of myocardial infarction and death were also not different between treatment 
groups. Similarly, risks of major bleeding and the composite NMCR bleeding and major 
bleeding were not different in those receiving rivaroxaban versus warfarin.
In the Subset of TI Patients Undergoing a Surgical/ Invasive Procedure—More 
than 40% of TI patients (2130) experienced TI for a surgical or invasive procedure, and their 
outcomes are shown in Table 5. The risk of stroke or non-CNS systemic embolism during 
any at-risk period of TI for a surgical or invasive procedure was not significantly different in 
rivaroxaban-treated patients versus warfarin-treated patients. Risks of myocardial infarction 
and death were also not different between treatment groups. Risks of major bleeding and the 
composite NMCR bleeding and major bleeding were not different in those receiving 
rivaroxaban versus warfarin in this subset of TIs. Results for a sensitivity analysis evaluating 
all TIs excluding those specifically for a bleeding event showed no differences between 
treatment arms, consistent with the aforementioned results (Table I in the online-only Data 
Supplement).
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By Timing of Study Drug Discontinuation—The occurrence of bleeding outcomes in 
relation to cessation of study drug before an invasive procedure is shown in Table 6. For the 
majority of TIs due to invasive procedures (90%; 2299/2547), study drug was stopped ≥3 
days before the procedure. The vast majority of bleeding events also occurred in this group 
(88%; 61/69), although the distribution and frequency were similar to those in the other 
groups.
By Use of Bridging Therapy—Outcomes according to use of bridging therapy are 
depicted in Table 7. Stroke/systemic embolism rates during TIs with bridging compared 
with those without bridging were not different. Rates of major bleeding were similar 
between bridged and nonbridged TIs, whereas rates of major/NMCR bleeding appeared 
numerically higher in patients receiving bridging therapy (4.83% versus 3.02%).
Discussion
This analysis of the ROCKET AF trial population represents one of the largest TI cohorts 
ever studied, with nearly 4700 participants experiencing >7000 TI and 431 participants 
receiving bridging therapy. The majority of TI episodes in ROCKET AF were due to 
invasive procedures (40%); however, a considerable proportion of TIs were also secondary 
to bleeding-related events and patient factors. Our report on this broad population is the first 
of its kind for novel oral anticoagulant therapy. Patterns of TI were due to a variety of minor 
and major invasive medical procedures, which are similar to those in prior observational 
studies.9,11 Duration of TI was often short (5 days) in our population, and bridging therapy 
with enoxaparin or fondaparinux was used in only 6% of TIs. TI was associated with a 30-
day stroke/systemic embolism rate of 0.36% and major bleeding rate of 0.88%, which is 
notable compared with the overall rates in the ROCKET trial of 2.2%/y and 3.5%/y, 
respectively.3 However, the risks of stroke/systemic embolism and clinically relevant 
bleeding associated with TI were similar in rivaroxaban- and warfarin-treated participants.
Characteristics of TI
Participants treated with warfarin had higher rates of TI compared with those on rivaroxaban 
in our analyses. Although clinicians might surmise that the higher rate of TI in warfarin 
patients would be due to a greater rate of adverse events or procedures, risks of adverse 
events and surgical/invasive procedures were similar among participants in both treatment 
groups experiencing TI. Participants and investigators were blinded and a double dummy 
procedure was in place, and therefore bias from knowledge of working with warfarin was 
mostly eliminated. There may have been incidences of pseudo-unblinding that were not 
documented, possibly by performing coagulation measures as part of a routine screening 
before surgical/invasive procedures or during adverse events. This may account for part of 
the discrepancy seen between warfarin and rivaroxaban, which is admittedly difficult to 
explain in this context.
Stroke With TI
The 30-day rate of stroke or non-CNS embolism in our study population was 0.36%, which 
is notable compared with the overall stroke/systemic embolism rate in the ROCKET AF trial 
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of 2.2%/y.3 The observed embolic event rates are high if prorated over a 1-year period but 
are consistent with findings in other populations in which there is TI of anticoagulant 
therapy.8 Possible factors that explain such higher-than-expected rates of embolic events 
include a prothrombotic perioperative milieu among patients having TI for surgery and a 
prothrombotic milieu associated with TI due to bleeding. In addition, patients enrolled in the 
ROCKET AF trial were considered high risk, and the embolic event rate during TI likely 
also reflects their intrinsic susceptibility to such outcomes. Our finding neither supports nor 
refutes a “rebound effect” with TI of either anticoagulant, especially given the short period 
(median=5 days) of anticoagulant interruption, and the clinical evidence for this 
phenomenon remains tenuous.15 Although differences were seen in stroke rates in the end-
of-study analyses of the ROCKET AF trial, we believe that this was due to the unbalanced 
(worse in rivaroxaban patients) lack of continuous therapeutic anticoagulation at the end of 
the study period; this has been described elsewhere.17 However, the results compare 
favorably with a recently published large meta-analysis of patients on vitamin K antagonists 
receiving bridging or no bridging therapy in the periprocedural setting.8 That study 
described an acute thromboembolism event rate of ≈ 1.0% and a rate of periprocedural 
stroke/systemic embolism events of ≈ 1%.8 In addition, the risk of stroke/systemic 
embolism events compares favorably to the only other published database of periprocedural 
outcomes with the novel oral anticoagulant dabigatran in a lower-risk population as part of 
the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, with a 
30-day acute thromboembolism event rate of 1%, with ≈ 17% of patients receiving heparin 
bridging therapy.12 In our study, there was no detectable difference in the risk of stroke and 
systemic embolism for participants treated with rivaroxaban versus warfarin undergoing TI, 
consistent with the overall trial results.3
Bleeding With TI
Bleeding rates in those experiencing TI can be significant.9,18,19 The aforementioned large 
meta-analysis described a 30-day major bleeding rate of ≈ 4% in warfarin-treated patients in 
periprocedural settings, with bridging therapy conferring a >3-fold increase risk of major 
bleeding.8 In our study, participants who underwent TI for invasive procedures had rates of 
major bleeding and NMCR bleeding of ≈ 1% and 3% per 30 days, respectively, which were 
similar between treatment groups. This finding was consistent with data from the main trial, 
which showed that rates of major and NMCR bleeding were similar (14.9% versus 14.5% 
per year; P=0.44) between treatment groups.3 This is also consistent with periprocedural 
data from the RE-LY trial, which showed major bleeding and minor bleeding rates of ≈ 4% 
and ≈ 8%, respectively. Thus, our data in a high-risk population with AF on chronic 
anticoagulation in periprocedural settings compare favorably with previous evidence for 
postprocedural major bleeding rates with vitamin K antagonists and dabigatran.12
Patterns of Bridging Therapy
The use of bridging therapy was infrequent, at 6% of all TIs in the on-treatment safety 
population despite the moderate-to high-risk nature of this group (mean CHADS2 
score=3.4). This observation was similar to data from Garcia et al,11 showing that rates of 
bridging were low (8.3%) in an observational cohort of chronically anticoagulated 
participants with diverse indications. Current guidelines indicate that the thromboembolic 
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risk of TI should be estimated and weighed against the estimated risk of perioperative 
bleeding, and then bridging therapy should be utilized predominantly in the individuals at 
highest risk of thromboembolism.5 A possible explanation for the pattern of therapy seen in 
our analyses may be due to the blinding of participants and investigators in the ROCKET 
AF trial. Often clinicians are hesitant to introduce a second anticoagulant therapy to a patient 
experiencing TI if they are unsure of the current status of anticoagulation (in this case, 
because they are blinded to therapy). This may have led to the very low rates of bridging 
therapy utilization observed in this study. Participants were predominantly bridged with 
low-molecular-weight heparin in this analysis, consistent with current guideline 
recommendations.5
The rates of major bleeding were ≈ 1% among TIs with bridging therapy, whereas only 1 
stroke or systemic embolism occurred in our small group. This is consistent with recent 
meta-analyses data showing low rates of thromboembolism (<1%) and bleeding (≈4%) in 
patients on chronic vitamin K antagonist therapy undergoing elective procedures with and 
without heparin bridging.8 Significance testing was not performed because of the small 
absolute number of events in the relatively small set of TIs that were bridged and because of 
the confounding present between bridged and unbridged TIs in the same participants. 
However, the data raise the question of whether the benefit of lower thrombotic events 
might be mitigated by an increased risk of bleeding associated with bridging 
anticoagulation. Current data available to answer this question are mixed,9,10,18 and there is 
no clear consensus to the risks and potential benefits of bridging therapy. Although 
published guidelines exist in regard to the management of novel oral anticoagulants in the 
periprocedural setting,15 they are based primarily on expert opinion, with little evidence to 
drive clinical management. Further work on this topic, including whether there is a role for 
heparin bridging therapy in patients on rivaroxaban in periprocedural settings, is needed.
Limitations
Our study has several limitations. First, it is a retrospective analysis of clinical trial data, and 
thus there is likely selection bias in regard to patient patterns of TI and bridging therapy. 
However, a particular strength of the analyses is that all participants and investigators were 
blinded to treatment assignment. Thus, the majority of comparisons made in this study were 
between the randomized treatment groups from the original trial, which should strengthen its 
validity by mitigating intentional biases. We acknowledge that utilization of bridging 
therapy was not randomized, and therefore any comparisons made between bridged and 
unbridged TIs may be subject to multiple biases. Thus, we chose to limit these comparisons. 
Although our study represents one of the largest populations of TI participants studied, with 
a large number of temporary interruptions, the number of events compared between groups 
is low. As a post hoc analysis, there was insufficient power to compare the TI subpopulation 
with the overall ROCKET AF population and examine the effect of TIs on clinical 
outcomes. In addition, because these are nonrandomized comparisons and because of the 
low number of events, we did not pursue multivariable statistical modeling. In addition, we 
did not have full and detailed data for the characteristics of these temporary interruptions, 
including the urgency (eg, elective versus emergent) of the surgical or invasive procedures 
leading to TI, as well as the relationship of study drug restart to the date of potential surgical 
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or invasive procedures. Finally, for 11% of TIs due to surgical/invasive procedures, we did 
not have details on type, indication, or duration of that procedure. Lacking these data limited 
the depth of analyses that could be performed for the outcomes of TI.
Conclusions
In the ROCKET AF study, a large international population of participants with nonvalvular 
AF, TI of oral anticoagulation occurred in ≈ 10% of patients per year, with only a minority 
of patients (<10%) receiving bridging therapy. During the at-risk period associated with TIs, 
we observed a 30-day stroke/systemic embolism rate of 0.4% and a major bleeding rate of 
0.9%. The risks of thrombotic and bleeding complications were comparable between 
rivaroxaban- and warfarin-treated participants experiencing TI. TI of oral anticoagulation 
should be avoided to minimize adverse outcomes. Given the lack of randomized data in this 
area, further research is necessary to determine the safest way to manage both warfarin and 
novel anticoagulant medications, such as rivaroxaban, during TIs.
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CLINICAL PERSPECTIVE
The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin 
K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation 
(ROCKET AF) demonstrated that rivaroxaban was noninferior to warfarin in the 
prevention of stroke and systemic thromboembolic events in moderate- to high-risk 
participants with nonvalvular atrial fibrillation. During the course of the trial, many 
participants required temporary interruption of anticoagulant medication for surgery, 
invasive procedures, or adverse events. Our analysis provides one of the largest 
experiences of patients undergoing temporary interruption of oral anticoagulation for 
procedural and nonprocedural reasons and is one of the first to evaluate this clinical 
scenario in patients treated with a novel oral anticoagulant. In this clinical trial setting, 
the use of bridging anticoagulation was very low despite the high thrombotic risk of the 
population. There was no difference in thrombotic or bleeding events during or after 
temporary interruption in patients treated with rivaroxaban compared with patients 
treated with warfarin. However, given the substantial thrombotic and bleeding risks 
associated with temporary interruption of oral anticoagulation, it should be avoided if at 
all possible.
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Figure 1. 
Cumulative incidence plot of time to first temporary interruption by treatment group, 
showing the longitudinal analysis for time to first temporary interruption for warfarin- and 
rivaroxaban-treated patients. Warfarin-treated patients were significantly more likely to 
experience temporary interruption during follow-up.
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Figure 2. 
Distribution of surgical/invasive procedures requiring temporary interruption, showing the 
frequency of different types of surgical procedures that were listed as reasons for temporary 
interruptions in the Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared 
With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation (ROCKET AF). Abd indicates abdominal; Bx, biopsy; CABG, coronary artery 
bypass graft; EP, electrophysiology; GI, gastrointestinal; Ortho, orthopedic; PCI, 
percutaneous coronary intervention; and Thora, thoracic.
Abd = Abdominal, Thora = Thoracic, Ortho = Orthopedic, Bx = Biopsy, EP = 
Electrophysiology, PCI = Percutaneous coronary intervention, CABG = Coronary artery 
bypass graft
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Table 1
Baseline Characteristics of Temporary Interruption Participants
Characteristic
All Patients in Safety/On-
Treatment Population 
(n=14 236)
Patients With Temporary Interruption
All (n=4692) Rivaroxaban (n=2165) Warfarin (n=2527)
Age, y, median (25th, 75th percentiles) 73 (65, 78) 73 (66, 78) 73 (66, 78) 73 (66, 78)
Female, n (%) 5645 (39.7) 1714 (36.5) 765 (35.3) 949 (37.6)
BMI, kg/m2, median (25th, 75th 
percentiles)
28.2 (25.1, 32.0) 28.4 (25.4, 32.3) 28.6 (25.4, 32.4) 28.3 (25.4, 32.1)
Blood pressure, systolic, mm Hg, median 
(25th, 75th percentiles)
130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140)
Blood pressure, diastolic, mm Hg, median 
(25th, 75th percentiles)
80 (70, 85) 80 (70, 85) 80 (70, 85) 80 (70, 85)
Treatment exposure period, day, median 
(25th, 75th percentiles)
590 (399, 807) 674 (473, 864) 677 (477, 868) 673 (467, 857)
Type of atrial fibrillation, n (%)
 Persistent 11 525 (81.0) 3753 (80.0) 1740 (80.4) 2013 (79.7)
 Paroxysmal 2511 (17.6) 879 (18.7) 397 (18.3) 482 (19.1)
 Newly diagnosed or new onset 200 (1.4) 60 (1.3) 28 (1.3) 32 (1.3)
Prior chronic aspirin, n (%) 5194 (36.5) 1727 (36.8) 814 (37.6) 913 (36.2)
Prior vitamin K antagonist, n (%) 8889 (62.4) 3030 (64.6) 1388 (64.1) 1642 (65.0)
CHADS2 score, mean (SD) 3.47 (0.94) 3.41 (0.95) 3.40 (0.95) 3.42 (0.96)
 1 3 (<0.1) 2 (<0.1) 0 (0.0) 2 (0.1)
 2 1855 (13.0) 740 (15.8) 344 (15.9) 396 (15.7)
 3 6203 (43.6) 2029 (43.2) 942 (43.5) 1087 (43.0)
 4 4085 (28.7) 1280 (27.3) 595 (27.5) 685 (27.1)
 5 1809 (12.7) 549 (11.7) 243 (11.2) 306 (12.1)
 6 281 (2.0) 92 (2.0) 41 (1.9) 51 (2.0)
History of stroke, TIA, embolism, n (%) 7794 (54.7) 2358 (50.2) 1077 (49.7) 1281 (50.7)
History of CHF, n (%) 8894 (62.5) 2926 (62.4) 1344 (62.1) 1582 (62.6)
History of hypertension, n (%) 12 887 (90.5) 4273 (91.1) 1959 (90.5) 2314 (91.6)
History of diabetes mellitus, n (%) 5683 (39.9) 1955 (41.7) 926 (42.8) 1029 (40.7)
History of myocardial infarction, n (%) 2460 (17.3) 874 (18.6) 375 (17.3) 499 (19.7)
Peripheral vascular disease, n (%) 836 (5.9) 303 (6.5) 131 (6.1) 172 (6.8)
COPD, n (%) 1493 (10.5) 573 (12.2) 250 (11.5) 323 (12.8)
Creatinine clearance (Cockcroft-Gault 
equation), mL/min, median (25th, 75th 
percentiles)
67 (52, 87) 68 (53, 88) 68 (54, 89) 67 (52, 86)
Temporary interruptions, median (25th, 
75th percentiles)
0 (0, 1) 1 (1,2) 1 (1,2) 1 (1,2)
 0 9544 (67.0)
 1 2958 (20.8) 2958 (63.0) 1399 (64.6) 1559 (61.7)
 2 1118 (7.9) 1118 (23.8) 517 (23.9) 601 (23.8)
 3 347 (2.4) 347 (7.4) 150 (6.9) 197 (7.8)
 4 153 (1.1) 153 (3.3) 54 (2.5) 99 (3.9)
 5 54 (0.4) 54 (1.2) 19 (0.9) 35 (1.4)
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Characteristic
All Patients in Safety/On-
Treatment Population 
(n=14 236)
Patients With Temporary Interruption
All (n=4692) Rivaroxaban (n=2165) Warfarin (n=2527)
 6–18 62 (0.4) 62 (1.3) 26 (1.2) 36 (1.4)
BMI indicates body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; and TIA, transient ischemic attack.
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Table 2
Characteristics of TIs
Characteristic All TIs (n=7555)
TIs Among Rivaroxaban-
Treated Patients (n=3393)
TIs Among Warfarin-
Treated Patients 
(n=4162)
Duration of interruption, d, median (25th, 75th 
percentiles)
5 (4, 9) 6 (4, 10) 5 (4, 9)
Duration of risk period for events, d, median (25th, 75th 
percentiles)
35 (33, 38) 35 (33, 39) 35 (33, 38)
Reason for interruption,* n (%)
 Surgical/invasive procedure 2997 (39.7) 1309 (38.6) 1688 (40.6)
 Adverse event: nonbleeding 1874 (24.8) 816 (24.0) 1058 (25.4)
 Subject error 1366 (18.1) 624 (18.4) 742 (17.8)
 Adverse event: bleeding 995 (13.2) 540 (15.9) 455 (10.9)
 Logistic difficulty 449 (5.9) 163 (4.8) 286 (6.9)
 Site error 48 (0.6) 22 (0.6) 26 (0.6)
 Reason unknown 23 (0.3) 3 (0.1) 20 (0.5)
TIs with bridging therapy n=483 (6.4) n=277 (8.2) n=206 (4.9)
Type of bridging therapy, n (%)
 Fondaparinux 7 (1.4) 6 (2.2) 1 (0.5)
 LMWH 476 (98.6) 271 (97.8) 205 (99.5)
 Duration of bridging therapy, d, median (25th, 75th 
percentiles)
6 (4, 9) 6 (4, 10) 6 (4, 8)
LMWH indicates low-molecular-weight heparin; and TI, temporary interruption.
*
More than 1 reason could be provided for each TI.
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Table 3
Population Characteristics of Participants Who Underwent Bridging
Characteristic
Bridging Therapy at Least Once
Yes (n=431) No (n=4261) P Value
Age, y, median (25th, 75th percentiles) 74 (68, 78) 73 (65, 78) 0.019
Female, n (%) 140 (32.5) 1574 (36.9) 0.067
BMI, kg/m2, median (25th, 75th percentiles) 28.8 (26.0, 32.1) 28.4 (25.4, 32.3) 0.22
Blood pressure, systolic, mm Hg, median (25th, 75th percentiles) 130 (120, 140) 130 (120, 140) 0.81
Blood pressure, diastolic, mm Hg, median (25th, 75th percentiles) 80 (70, 85) 80 (70, 85) 0.91
Type of atrial fibrillation, n (%) 0.44
 Persistent 338 (78.4) 3415 (80.1)
 Paroxysmal 85 (19.7) 794 (18.6)
 Newly diagnosed or new onset 8 (1.9) 52 (1.2)
Prior chronic aspirin, n (%) 124 (28.8) 1603 (37.6) 0.0003
Prior vitamin K antagonist, n (%) 340 (78.9) 2690 (63.1) <0.0001
CHADS2 score, mean (SD) 3.52 (0.93) 3.40 (0.96) 0.0094
 1 0 (0.0) 2 (<0.1)
 2 41 (9.5) 699 (16.4)
 3 203 (47.1) 1826 (42.9)
 4 117 (27.1) 1163 (27.3)
 5 60 (13.9) 489 (11.5)
 6 10 (2.3) 82 (1.9)
History of stroke, TIA, embolism, n (%) 226 (52.4) 2132 (50.0) 0.34
History of CHF, n (%) 261 (60.6) 2665 (62.5) 0.42
History of hypertension, n (%) 390 (90.5) 3883 (91.1) 0.66
History of diabetes mellitus, n (%) 207 (48.0) 1748 (41.0) 0.0049
History of myocardial infarction, n (%) 73 (16.9) 801 (18.8) 0.34
Peripheral vascular disease, n (%) 44 (10.2) 259 (6.1) 0.0009
COPD, n (%) 51 (11.8) 522 (12.3) 0.80
Creatinine (Cockcroft-Gault equation), mL/min, median (25th, 75th percentiles) 67 (53, 84) 68 (53, 88) 0.74
Temporary interruptions, median (25th, 75th percentiles) 1 (1, 2) 1 (1, 2) <0.0001
 1 224 (52.0) 2734 (64.2)
 2 125 (29.0) 993 (23.3)
 3 59 (13.7) 288 (6.8)
 4 15 (3.5) 138 (3.2)
 5 4 (0.9) 50 (1.2)
 6–18 4 (0.9) 58 (1.4)
BMI indicates body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; and TIA, transient ischemic attack.
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Table 7
Outcomes During TIs With and Without Bridging Therapy
Events
Bridging Therapy (n=483 TIs) No Bridging Therapy (n=7072 TIs)
No. of Events Event Rate per 30 d, % No. of Events Event Rate per 30 d, %
Stroke/systemic embolism 1 0.17 31 0.37
Death 2 0.33 14 0.17
MI 4 0.69 25 0.30
Stroke/systemic embolism/MI/death 5 0.86 67 0.82
Major/NMCR bleeding 22 4.83 184 3.02
Major bleeding 5 0.91 69 0.88
Stroke/systemic embolism/MI/death as a composite does not include multiple events in the same patient. MI indicates myocardial infarction; 
NMCR, nonmajor clinically relevant; and TI, temporary interruption.
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